IN2015DN02573A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02573A
IN2015DN02573A IN2573DEN2015A IN2015DN02573A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A IN 2573DEN2015 A IN2573DEN2015 A IN 2573DEN2015A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A
Authority
IN
India
Prior art keywords
pulmonary fibrosis
compound
present
formula
idiopathic
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf; Nilsson
Hakon; Leffler
Neil; Henderson
Tariq; Sethi
Alison; Mackinnon
Original Assignee
Galecto Biotech Ab
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2794066A external-priority patent/CA2794066C/en
Priority claimed from US13/832,672 external-priority patent/US9243021B2/en
Application filed by Galecto Biotech Ab, Univ Edinburgh filed Critical Galecto Biotech Ab
Publication of IN2015DN02573A publication Critical patent/IN2015DN02573A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/001—Details of inhalators; Constructional features thereof with means for agitating the medicament using ultrasonic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2573DEN2015 2012-10-31 2013-10-30 IN2015DN02573A (uk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261720641P 2012-10-31 2012-10-31
CA2794066A CA2794066C (en) 2012-10-31 2012-10-31 Galactoside inhibitor of galectins
CA2795753A CA2795753A1 (en) 2012-10-31 2012-11-15 Novel galactoside inhibitor of galectins
US13/832,672 US9243021B2 (en) 2012-10-31 2013-03-15 Galactoside inhibitor of galectins
PCT/EP2013/072691 WO2014067986A1 (en) 2012-10-31 2013-10-30 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
IN2015DN02573A true IN2015DN02573A (uk) 2015-09-11

Family

ID=52686686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2573DEN2015 IN2015DN02573A (uk) 2012-10-31 2013-10-30

Country Status (7)

Country Link
EP (2) EP2914269B1 (uk)
JP (1) JP2015535233A (uk)
CN (1) CN104755088A (uk)
CA (1) CA2884802A1 (uk)
ES (1) ES2817888T3 (uk)
IN (1) IN2015DN02573A (uk)
WO (1) WO2014067986A1 (uk)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
JP6735680B2 (ja) * 2014-07-09 2020-08-05 ガレクト バイオテック エービー ガレクチンの新規ハイブリッドガラクトシド阻害剤
ES2776255T3 (es) 2015-01-16 2020-07-29 Galecto Biotech Ab Novedoso inhibidor de galactósido de galectinas
US10774102B2 (en) 2015-01-30 2020-09-15 Galecto Biotech Ab Galactoside inhibitor of galectins
EP3294293B1 (en) 2015-05-12 2020-11-18 Galecto Biotech AB Once-daily treatment of pulmonary fibrosis
JP6915956B2 (ja) * 2015-05-15 2021-08-11 ガレクト・バイオテック・エイビイ 肺線維症の１日１回の治療
US10799522B2 (en) * 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
ES2921500T3 (es) * 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas
CN108602847A (zh) * 2015-12-18 2018-09-28 格莱克特生物技术公司 多晶型及方法
EP3423461A4 (en) * 2016-03-04 2020-03-25 Galectin Sciences, LLC SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES RELATING TO GALECTIN AND THE USE THEREOF
JP7038099B2 (ja) 2016-07-12 2022-03-17 ガレクト バイオテック エービー ガレクチンのα－Ｄ－ガラクトシド阻害剤
CA3025867A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
US11267811B2 (en) 2017-09-27 2022-03-08 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
CN111699193A (zh) 2018-01-10 2020-09-22 格莱克特生物技术公司 新型半乳糖苷类半乳凝素抑制剂
JP7471660B2 (ja) * 2018-05-17 2024-04-22 アクチュエイト セラピューティクス インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
WO2019241461A1 (en) 2018-06-15 2019-12-19 Bristol-Myers Squibb Company Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors
EP3813883A1 (en) 2018-06-29 2021-05-05 Glykos Biomedical Oy Conjugates
WO2020078807A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Prodrug of galactoside inhibitors of galectins
CA3113956A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Galactoside inhibitor of galectins
US11447517B2 (en) 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
WO2020117883A1 (en) 2018-12-06 2020-06-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CA3122321A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
KR20210143255A (ko) 2019-03-26 2021-11-26 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
KR20210150485A (ko) 2019-04-10 2021-12-10 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
CA3138668A1 (en) * 2019-06-14 2020-12-17 Denis Giguere Synthesis of 3-azido-3-deoxy-d-galactopyranose
JP2022537737A (ja) 2019-06-24 2022-08-29 ガレクト バイオテック エービー ３，３’－ジデオキシ－３，３’－ビス－［４－（３－フルオロフェニル）－１ｈ－１，２，３－トリアゾル－１－イル］－１，１’－スルファンジイル－ジ－ベータ－ｄ－ガラクトピラノシドの大規模方法
EP3993872A1 (en) 2019-07-03 2022-05-11 Galecto Biotech AB Novel galactoside inhibitor of galectins
CA3141436A1 (en) 2019-07-03 2021-01-07 Fredrik Zetterberg Novel galactoside inhibitor of galectins
US20220259251A1 (en) 2019-07-05 2022-08-18 Galecto Biotech Ab Novel galactoside inhibitor of galectins
TW202120102A (zh) 2019-08-09 2021-06-01 瑞士商愛杜西亞製藥有限公司 (雜)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
CN114269737A (zh) 2019-08-15 2022-04-01 爱杜西亚药品有限公司 2-羟环烷-1-胺甲酰基衍生物
HRP20240297T1 (hr) 2019-08-29 2024-05-10 Idorsia Pharmaceuticals Ltd Derivati alfa-d-galaktopiranozida
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
WO2021195020A1 (en) * 2020-03-23 2021-09-30 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
US20230137160A1 (en) 2020-03-31 2023-05-04 Galecto Biotech Ab Large scale process for preparing 1,2,4, 6-tetra-o-acetyl-3-azido-3-deoxy-d-galactopyranoside
JP2023524996A (ja) 2020-05-05 2023-06-14 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
WO2021231243A1 (en) 2020-05-11 2021-11-18 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US20230303538A1 (en) 2020-05-28 2023-09-28 Bristol-Myers Squibb Company Galectin-3 inhibitors
CN116348463A (zh) 2020-10-06 2023-06-27 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷的螺衍生物
TW202233609A (zh) 2020-11-02 2022-09-01 瑞士商愛杜西亞製藥有限公司 2-羥環烷-1-胺甲醯基衍生物
IL304923A (en) 2021-02-09 2023-10-01 Idorsia Pharmaceuticals Ltd History of hydroxyheterocycloalkane-carbamoyl
MX2023010241A (es) 2021-03-03 2023-09-12 Idorsia Pharmaceuticals Ltd Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE33447T1 (de) 1984-08-09 1988-04-15 Brugger Inge Zerstaeubervorrichtung.
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
JP2000503565A (ja) 1996-01-03 2000-03-28 グラクソ、グループ、リミテッド 吸入装置
DE19726110C2 (de) 1997-06-20 1999-07-22 Draegerwerk Ag Aerosolgenerator für Beatmungssysteme
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
ATE269735T1 (de) 2001-10-18 2004-07-15 Pari Gmbh Inhalationstherapievorrichtung
AU2002343094A1 (en) * 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
ATE463304T1 (de) 2002-08-02 2010-04-15 Pari Pharma Gmbh Vorrichtung zur erzeugung von flüssigkeitströpfchen
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US20080249144A1 (en) * 2004-07-22 2008-10-09 Kaken Pharmaceuitical Co., Ltd. Preventive or Therapeutic Agent for Chronic Inflammatory Lung Disease
US8703720B2 (en) 2009-04-28 2014-04-22 Galecto Biotech Ab Galactoside inhibitors of galectins
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
CA3042808A1 (en) * 2011-04-12 2012-10-18 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Also Published As

Publication number Publication date
JP2015535233A (ja) 2015-12-10
CN104755088A (zh) 2015-07-01
WO2014067986A8 (en) 2016-04-14
EP2914269B1 (en) 2020-07-29
EP3278805A1 (en) 2018-02-07
WO2014067986A1 (en) 2014-05-08
EP2914269A1 (en) 2015-09-09
CA2884802A1 (en) 2014-05-08
ES2817888T3 (es) 2021-04-08

Similar Documents

Publication Publication Date Title
IN2015DN02573A (uk)
NZ708501A (en) Treatment of pulmonary disease
IN2015DN01156A (uk)
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
MX2015015412A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
EP2823043A4 (en) HIGHLY CONCENTRATED ALPHA-GLUCOSIDASE COMPOSITIONS FOR THE TREATMENT OF MORBUS POMPE
EP2827869A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
PH12015501494A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
MX2015007916A (es) Peri-carbinoles.
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
TN2014000095A1 (en) Pharmaceutical compositions
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MX2015008187A (es) Inhibidores de alk deuterados.
PH12014500990A1 (en) Methods for treating gout flares
MX347541B (es) Analogos de acido sialico.
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
PH12014502065A1 (en) Vesicular formulations
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
TN2014000227A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines